Per-Irradiation Monitoring by kV-2D Acquisitions in Stereotactic Treatment of Spinal and Non-Spinal Bony Metastases Using an On-Board Imager of a Linear Accelerator.

Background/objectives: An on-board imager on a linear accelerator allows the acquisition of kV-2D images during irradiation. Overlaying specific structures on these images enables the visual verification of movement at regular frequencies. Our aim was to validate this tracking method for the stereotactic treatment of bone metastases.

Enhancing dosimetric practices through knowledge-based predictive models: a case study on VMAT prostate irradiation.

Introduction: Acquisition of dosimetric knowledge by radiation therapy planners is a protracted and complex process. This study delves into the impact of empirical predictive models based on the knowledge-based planning (KBP) methodology, aimed at detecting suboptimal results and homogenizing and improving existing practices for prostate cancer. Moreover, the dosimetric effect of implementing these models into routine clinical practice was also assessed.

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).

Background: The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neutropenia-inducing chemotherapy (CT).

Methods: Patients ≥ 18 years undergoing CT for a malignant disease and with a first prescription for Zarzio® were enrolled in two cohorts according to tumour type: solid tumour or haematological malignancy; results from the solid tumour cohort are reported here. Analyses primarily described the prescription and use of Zarzio® in current practice, and also included identification of factors linked to prescription for primary prophylaxis and comparison of Zarzio® use in relation to European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Background: The prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.

[Audits of the quality management system and safety in radiotherapy: Lessons learned and future prospects].

The external audit of the management system of quality and safety in radiotherapy by quality managers of the French Association of Quality and Safety in Radiotherapy (AFQSR) is an opportunity to exchange good practices, returns of experience, effectiveness and weaknesses of the quality system, and its perceptions by all the teams. We present the results of the first audits conducted, and the results of a survey on the perception of quality at national level.

A prospective observational study assessing home parenteral nutrition in patients with gastrointestinal cancer: benefits for quality of life.

Context: Patients with gastrointestinal cancer are at high risk for deterioration of nutrition. Home parenteral nutrition (HPN) could improve nutritional status and quality of life (QoL).

Objectives: The purpose of this study was 1) to evaluate the impact of HPN on QoL, 2) to assess changes in nutritional status, and 3) to assess proxy perception of patient well-being.

[Home parenteral nutrition in elderly patients with cancer: an observational prospective study].

Malnutrition is a bad prognostic factor that reduces the quality of life (QoL) in patients with cancer. The objective was to assess the impact of home parenteral nutrition (HPN) on the QoL of elderly malnourished patients with cancer. This French prospective observational study included patients, aged 70 years or older, with cancer, for whom HPN was prescribed for at least 14 days.

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

Purpose: The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alpha given with IV iron versus with local standard practice (oral iron or no iron).

Patients And Methods: In this multicenter, randomized, open-label, phase III study, 396 patients with nonmyeloid malignancies and hemoglobin (Hb) less than 11 g/dL received darbepoetin alpha 500 microg with (n = 200) or without (n = 196) IV iron once every 3 weeks (Q3W) for 16 weeks.